58096-78-9

Basic information

• Product Name: Hexa-N-(benzyloxycarbonyl)neomycin B
• Synonyms: Hexa-N-(benzyloxycarbonyl)neomycin B
• CAS NO: 58096-78-9
• Molecular Weight: 1419.46
• Mol File: 58096-78-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Hexa-N-(benzyloxycarbonyl)neomycin B(CAS DataBase Reference)
• NIST Chemistry Reference: Hexa-N-(benzyloxycarbonyl)neomycin B(58096-78-9)
• EPA Substance Registry System: Hexa-N-(benzyloxycarbonyl)neomycin B(58096-78-9)

Safety Data

• Hazardous Substances Data: 58096-78-9(Hazardous Substances Data)

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 4146-30-9 neomycin B trisulfate 
• 119-04-0 neomycin B 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 501-53-1 benzyl chloroformate 
• 25389-98-4 neomycin B sulphate 

Downstream Products

• 1284283-30-2 C₉₂H₉₄N₆O₂₅ 
• 1215860-52-8 1,3,2',6',2''',6'''-hexa-Cbz-5''-OTBDPS-neomycin 
• 1215860-61-9 5''-O-trityl-1,3,2',6',2''',6'''-hexa-N-Cbz-neomycin B 
• 78763-85-6 1,3,2',6'-Tetra-N-(benzyloxycarbonyl)-6,3',4'-tri-O-benzylneamine 

Relevant articles and documents

A simple structural-based approach to prevent aminoglycoside inactivation by bacterial defense proteins. Conformational restriction provides effective protection against neomycin-B nucleotidylation by ANT4

Herein, we describe how the conformational differences exhibited by aminoglycosides in the binding pockets of the ribosome and those enzymes involved in bacterial resistance can be exploited in the design of new antibiotic derivatives with improved activi

Synthesis, separation, and characterization of amphiphilic sulfated oligosaccharides enabled by reversed-phase ion pairing LC and LC-MS methods

Synthesis of amphiphilic oligosaccharides is problematic because traditional methods for separating and purifying oligosaccharides, including sulfated oligosaccharides, are generally not applicable to working with amphiphilic sugars. We report here RPIP-L

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.